Volitionrx Stock Price, News & Analysis

VolitionRx (NYSE AMERICAN: VNRX) announced its silver sponsorship of the 44th Annual ISICEM Congress in Brussels, Belgium, from March 18-21, 2025. The company will support multiple presentations highlighting their Nu.Q® H3.1 epigenetic screening technology in intensive care and emergency medicine settings.

The congress will feature six presentations focusing on various aspects of NETosis, NETs, and nucleosomes-H3.1 in sepsis screening and monitoring. Dr. Andrew Retter, Volition's Chief Medical Officer, emphasized the significance of these studies in validating their technology's role in sepsis care, noting a potential $1B+ market opportunity in this sector.

Additionally, Dr. Retter will speak at the Praetorian Doctoral Network Satellite Symposium on March 19th, discussing the Nu.Q® test for measuring circulating H3.1 nucleosomes as markers for neutrophil extracellular traps in blood.

VolitionRx (NYSE AMERICAN: VNRX) has expanded its Nu.Q® Vet Cancer Test supply agreement with Fujifilm Vet Systems in Japan. The new five-year agreement includes Volition's chemiluminescent immunoassay (ChLIA) version via the IDS i10® automated analyzer platform.

The expansion builds upon the previous agreement that offered the manual ELISA format test. Fujifilm Vet Systems plans to launch the automated platform for canine cancer screening in summer 2025, following final validation and verification. Since the initial launch in July 2024, over 1,000 veterinary hospitals in Japan have registered to use the test.

The agreement allows Fujifilm Vet Systems to sell and perform the Nu.Q® Vet Cancer Test through its network of central reference laboratories in Japan, targeting a market of approximately seven million pet dogs.

VolitionRx (NYSE AMERICAN: VNRX) has announced the enrollment of its first patient in a clinical validation study for its Nu.Q® Cancer technology at National Taiwan University Hospital. The study aims to evaluate the technology's ability to differentiate between malignant and benign pulmonary nodules in patients undergoing low-dose computed tomography (LDCT) screening for lung cancer.

The 500-patient prospective validation study follows promising results from a previous study published on March 7th, 2025, which showed Nu.Q® Cancer's high sensitivity in identifying malignant nodules. The current study is expected to be completed by the end of 2025.

If successful, the Nu.Q® test could be integrated into national lung cancer screening programs, potentially reducing false positives and unnecessary invasive procedures. The blood-based test aims to support physicians in clinical decision-making by identifying high-risk patients and those who might avoid unnecessary biopsies.

VolitionRx (NYSE AMERICAN: VNRX) has signed an agreement with a leading pharmaceutical company to use its Nu.Q® Discover biomarkers in a longitudinal Phase 1/2b study. This marks the first human clinical study utilizing Volition's biomarkers with a pharmaceutical company sponsor.

The study will employ two Nu.Q® Discover assays to measure disease progression and treatment response, following a successful pilot study. The project is expected to span 12-18 months and generate significant revenue for Volition. The Nu.Q® Discover program offers drug developers rapid epigenetic profiling tools across various development stages.

Additional clinical studies are under discussion with this and other companies, potentially strengthening Volition's position in the pharmaco-epigenetics market. The biomarkers will be used to address an unmet medical need, though specific disease details were not disclosed.

VolitionRx (NYSE AMERICAN: VNRX) has announced its participation in the 97th Annual Western Veterinary Conference (WVC), scheduled for March 2-5, 2025, in Las Vegas. The conference, attracting approximately 20,000 veterinary professionals, will feature presentations about the company's Nu.Q® Vet Cancer Test.

The company will host three presentations by notable veterinary professionals: Dr. Sue Ettinger (Dr. Sue Cancer Vet), Dr. Brett Cordes, and Dr. Tom Butera. These sessions will focus on various aspects of the Nu.Q® Vet Cancer Test, including cancer journey navigation, practical implementation, and early detection screening. The test is designed to detect seven common cancers in dogs and is marketed as accessible, affordable, and easy-to-use with rapid results.

VolitionRx (NYSE AMERICAN: VNRX) has announced its first commercial sale of their High Throughput Synthetic Sepsis method, a breakthrough technology that measures Neutrophil Extracellular Traps (NETs) activation and inhibition in whole blood in real time. This innovative approach helps companies develop new therapeutics for sepsis and NETs-related diseases.

The technology addresses significant limitations in previous research by measuring NETs directly in whole blood, avoiding potential alterations in neutrophil responses caused by isolation procedures. The method provides a more physiologically relevant environment for studying neutrophil responses and enables precise measurement of NETs formation.

Sepsis, responsible for approximately 370,000 US deaths annually, involves NETs which are essential for trapping and neutralizing pathogens. However, their overproduction can lead to tissue damage and disease progression. This new technology aims to enhance understanding of conditions characterized by uncontrolled NETs formation and serve as a key tool in translational research.

VolitionRx (NYSE: VNRX) has announced a virtual investor event scheduled for February 14, 2025, at 8:00 AM ET. The event, titled 'Casting a New Light on Sepsis Management,' will feature presentations from Dr. Andrew Retter, Chief Medical Officer, and Gael Forterre, Chief Commercial Officer.

Dr. Retter will discuss Nu.Q® NETs H3.1, a novel biomarker for early mortality and organ dysfunction in sepsis, which also serves as an independent predictor for renal replacement therapy needs. Recent large-scale study results suggest potential clinical applications in risk stratification and early intervention for critically ill sepsis patients.

Mr. Forterre will provide updates on Volition's commercialization strategies through licensing and sales channels. The event will conclude with a live Q&A session.

VolitionRx (NYSE AMERICAN: VNRX) has announced significant results from a large-scale study of its Nu.Q®NETs H3.1 biomarker in sepsis patients. The study, analyzing plasma samples from 971 patients with sepsis and septic shock, demonstrates that the biomarker can independently predict 28-day mortality and need for renal replacement therapy.

The research reveals higher biomarker levels in septic shock compared to sepsis patients, showing a dose-response relationship with acute kidney injury severity. The study suggests Nu.Q® NETs H3.1's potential for risk stratification and early intervention in critically ill sepsis patients.

The company is currently engaged in commercial discussions with major diagnostic industry players, particularly focusing on the sepsis market. The technology aims to provide simple, cost-effective blood tests for disease diagnosis and monitoring in both humans and animals.

VolitionRx (NYSE AMERICAN: VNRX) has released its 2024 Business Review, highlighting significant achievements in expanding its diagnostic technologies. The company's Nu.Q® Vet Cancer Test reached 20 countries worldwide, with over 110,000 tests sold in the first three quarters of 2024.

Key developments include hosting a Satellite Symposium showcasing Nu.Q® NETs clinical utility in over 3,000 intensive care sepsis patients, strengthening their patent portfolio, and making progress in clinical and research programs within their cancer pillar. The company has initiated commercial discussions for out-licensing opportunities in sepsis and oncology liquid biopsy markets.

Volition also strengthened its Board of Directors with the appointment of Timothy Still as chair and Dr. Ethel Rubin as Independent Director, both bringing significant commercial and financing experience in diagnostics.